Centessa Pharmaceuticals (CNTA) Operating Income (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Operating Income of -$79.8 million for Q1 2026, down 159.2% year-over-year from $134.8 million in Q1 2025, and down 16.5% on a QoQ basis from -$68.5 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Operating Income data on file, last reported at -$79.8 million in Q1 2026.
- Quarterly Operating Income fell 159.2% year-over-year to -$79.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$256.7 million (down 31.14% YoY) and the FY2025 annual result came in at -$207.7 million, down 3.3% from the prior year.
- Operating Income retreated to -$79.8 million in Q1 2026 per CNTA's latest filing, from -$68.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$30.8 million in Q1 2025 and bottomed at -$79.8 million in Q1 2026.
- The 5-year median for Operating Income is -$48.9 million (2023), against an average of -$51.3 million.
- The widest annual swing landed in 2022, when Operating Income jumped 77.47%; it then tumbled 159.2% in 2026.
- Tracing CNTA's Operating Income over 5 years: stood at -$41.6 million in 2022, then advanced by 15.44% to -$35.2 million in 2023, then plunged by 112.01% to -$74.6 million in 2024, then grew by 8.19% to -$68.5 million in 2025, then declined by 16.5% to -$79.8 million in 2026.
- Per Business Quant, the three latest CNTA Operating Income figures stand at -$79.8 million (Q1 2026), -$68.5 million (Q4 2025), and -$53.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -79.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.77 Mn |
| Dec 31, 2025 | -68.47 Mn |
| Sep 30, 2025 | -53.79 Mn |
| Jun 30, 2025 | -54.65 Mn |
| Mar 31, 2025 | -30.78 Mn |
| Dec 31, 2024 | -74.58 Mn |
| Sep 30, 2024 | -46.41 Mn |
| Jun 30, 2024 | -43.98 Mn |
| Mar 31, 2024 | -36.09 Mn |
| Dec 31, 2023 | -35.18 Mn |
| Sep 30, 2023 | -40.21 Mn |
| Jun 30, 2023 | -47.02 Mn |
| Mar 31, 2023 | -48.88 Mn |
| Dec 31, 2022 | -41.60 Mn |
| Sep 30, 2022 | -49.03 Mn |
| Jun 30, 2022 | -68.41 Mn |
| Mar 31, 2022 | -53.22 Mn |
| Dec 31, 2021 | -58.29 Mn |
| Sep 30, 2021 | -38.31 Mn |
| Jun 30, 2021 | -41.29 Mn |
| Mar 31, 2021 | -236.19 Mn |
| Dec 31, 2020 | -3.01 Mn |
| Sep 30, 2020 | -2.12 Mn |
| Jun 30, 2020 | -2.13 Mn |